Literature DB >> 1445226

Lysosomal cysteine endopeptidases mediate interleukin 1-stimulated cartilage proteoglycan degradation.

D J Buttle1, J Saklatvala.   

Abstract

The peptidyl diazomethane inactivator of cysteine endopeptidases, benzyloxycarbonyl-Tyr-Ala-CHN2, was tested as an inhibitor of interleukin 1 alpha-stimulated release of proteoglycan from bovine nasal septum cartilage explants. Like the previously tested epoxidyl peptide proinhibitor trans-epoxysuccinyl-leucylamido-(3-methyl)butane ethyl ester, it proved to be an effective inhibitor of proteoglycan release from cartilage, with significant inhibition at a concentration of 1 microM. The inhibition did not seem to be due to a general toxic effect. The rates of inactivation of the bovine cysteine endopeptidases by the peptidyl diazomethane, the epoxidyl peptide proinhibitor and its active form were determined. Benzyloxycarbonyl-Tyr-Ala-CHN2 proved to be a rapid inactivator of cathepsins L, S and B, but reacted much more slowly with cathepsin H and calpain. Thus it would appear that the latter two enzymes are not implicated in proteoglycan release in our test system. The peptidyl diazomethane and epoxidyl peptide proinhibitor (above) were also tested for their effects on three other interleukin 1-mediated cellular events, namely epidermal growth factor receptor transmodulation, and interleukin 6 and prostaglandin E2 production. In all cases the inactivators did not interfere with the response to interleukin 1 in human gingival fibroblasts. We conclude that one or more of the lysosomal cysteine endopeptidases cathepsins B, L and S mediate interleukin 1-stimulated cartilage proteoglycan degradation without affecting signal transduction.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1445226      PMCID: PMC1133216          DOI: 10.1042/bj2870657

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  27 in total

Review 1.  Cytokines and transcription factors.

Authors:  K Muegge; S K Durum
Journal:  Cytokine       Date:  1990-01       Impact factor: 3.861

2.  How does interleukin 1 activate cells? Cyclic AMP and interleukin 1 signal transduction.

Authors:  S B Mizel
Journal:  Immunol Today       Date:  1990-11

3.  IL-1 and tumor necrosis factor synergistically stimulate fibroblast IL-6 production and stabilize IL-6 messenger RNA.

Authors:  J A Elias; V Lentz
Journal:  J Immunol       Date:  1990-07-01       Impact factor: 5.422

4.  FLUSYS: a software package for the collection and analysis of kinetic and scanning data from Perkin-Elmer fluorimeters.

Authors:  N D Rawlings; A J Barrett
Journal:  Comput Appl Biosci       Date:  1990-04

5.  Cartilage proteoglycan aggregate is degraded more extensively by cathepsin L than by cathepsin B.

Authors:  Q Nguyen; J S Mort; P J Roughley
Journal:  Biochem J       Date:  1990-03-01       Impact factor: 3.857

6.  Down-modulation of epidermal growth factor receptor affinity in fibroblasts treated with interleukin 1 or tumor necrosis factor is associated with phosphorylation at a site other than threonine 654.

Authors:  T A Bird; J Saklatvala
Journal:  J Biol Chem       Date:  1990-01-05       Impact factor: 5.157

7.  How does interleukin 1 activate cells? Interleukin 1 signal transduction.

Authors:  L A O'Neill; T A Bird; J Saklatvala
Journal:  Immunol Today       Date:  1990-11

8.  The importance of Val-157 hydrophobic interaction for papain inhibitory activity of an epoxysuccinyl amino acid derivative. A structure-activity relationship based on the crystal structure of the papain-E-64-c complex.

Authors:  D Yamamoto; K Matsumoto; H Ohishi; T Ishida; M Inoue; K Kitamura; K Hanada
Journal:  FEBS Lett       Date:  1990-04-09       Impact factor: 4.124

9.  Cathepsin B efficiently activates the soluble and the tumor cell receptor-bound form of the proenzyme urokinase-type plasminogen activator (Pro-uPA).

Authors:  H Kobayashi; M Schmitt; L Goretzki; N Chucholowski; J Calvete; M Kramer; W A Günzler; F Jänicke; H Graeff
Journal:  J Biol Chem       Date:  1991-03-15       Impact factor: 5.157

10.  Species variants of cathepsin L and their immunological identification.

Authors:  R W Mason
Journal:  Biochem J       Date:  1986-11-15       Impact factor: 3.857

View more
  7 in total

1.  Proteolytic mechanisms of cartilage breakdown: a target for arthritis therapy?

Authors:  D J Buttle; H Bramwell; A P Hollander
Journal:  Clin Mol Pathol       Date:  1995-08

2.  Expression of functional recombinant human procathepsin B in mammalian cells.

Authors:  W P Ren; R Fridman; J R Zabrecky; L D Morris; N A Day; B F Sloane
Journal:  Biochem J       Date:  1996-11-01       Impact factor: 3.857

3.  Temporal pattern of cysteine endopeptidase (cathepsin B) expression in cartilage and synovium from rabbit knees with experimental osteoarthritis: gene expression in chondrocytes in response to interleukin-1 and matrix depletion.

Authors:  F Mehraban; M H Tindal; M M Proffitt; R W Moskowitz
Journal:  Ann Rheum Dis       Date:  1997-02       Impact factor: 19.103

4.  Inhibitors of collagenase but not of gelatinase reduce cartilage explant proteoglycan breakdown despite only low levels of matrix metalloproteinase activity.

Authors:  C J Brown; S Rahman; A C Morton; C L Beauchamp; H Bramwell; D J Buttle
Journal:  Clin Mol Pathol       Date:  1996-12

5.  Cathepsin B in osteoarthritis: cytochemical and histochemical analysis of human femoral head cartilage.

Authors:  A Baici; A Lang; D Hörler; R Kissling; C Merlin
Journal:  Ann Rheum Dis       Date:  1995-04       Impact factor: 19.103

6.  A simple in vivo model of collagen degradation using collagen-gelled cotton buds: the effects of collagenase inhibitors and other agents.

Authors:  E H Karran; K Dodgson; S J Harris; R E Markwell; G P Harper
Journal:  Inflamm Res       Date:  1995-01       Impact factor: 4.575

7.  In vivo model of cartilage degradation--effects of a matrix metalloproteinase inhibitor.

Authors:  E H Karran; T J Young; R E Markwell; G P Harper
Journal:  Ann Rheum Dis       Date:  1995-08       Impact factor: 19.103

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.